Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pyoderma Gangrenosum: early-phase trial registry
2 of 4 indexed Pyoderma Gangrenosum trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Pyoderma Gangrenosum: 4 US clinical trials tracked, 2 recruiting.
Pyoderma Gangrenosum is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Oregon Health and Science University, running 2 of these trials.
Enrollment posture brief
Registry condition pyoderma-gangrenosum
OPEN 2 | RECR 50% | LATE 1 | EARLY 3 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Pyoderma Gangrenosum lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pyoderma Gangrenosum on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pyoderma Gangrenosum is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
Boehringer Ingelheim
NCT06624670
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
Oregon Health and Science University
NCT06563323
Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum
Xoma (US)
NCT01882504
Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
Oregon Health and Science University
NCT04901325
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Pyoderma Gangrenosum records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pyoderma Gangrenosum trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pyoderma Gangrenosum page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Pyoderma Gangrenosum trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Oregon Health and Science University sponsors the most Pyoderma Gangrenosum trials on record, review their full trial history before evaluating a specific study. See Oregon Health and Science University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pyoderma Gangrenosum condition card totals 4 registered trials; most-linked intervention gevokizumab; top US site state Oregon. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.